Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | APP | P05067 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | BLM | P54132 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1148624 | 0.94 | HSP90AA1 (0.35) | HSP90AA1HSP90AB1MEN1KMT2AAPP | |
| SCHEMBL12047170 | 0.83 | HSP90AA1 (0.35) | HSP90AA1HSP90AB1APPKDM4ESIGMAR1 | |
| SCHEMBL1148474 | 0.83 | HSP90AA1 (0.46) | HSP90AA1HSP90AB1 | |
| SCHEMBL4567031 | 0.83 | HSP90AA1 (0.34) | HSP90AA1HSP90AB1KMT2ASMN1; SMN2MAPT | |
| SCHEMBL14345687 | 0.79 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1 | |
| SCHEMBL12858610 | 0.78 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1 | |
| SCHEMBL1148626 | 0.77 | HSP90AA1 (0.36) | HSP90AA1HSP90AB1KDM4ENPC1RAB9A | |
| SCHEMBL12047265 | 0.77 | HSP90AA1 (0.49) | HSP90AA1HSP90AB1 | |
| SCHEMBL12047266 | 0.76 | PTGER1 (0.40) | HSP90AA1HSP90AB1PTGER1 | |
| SCHEMBL15370336 | 0.75 | HSP90AB1 (0.48) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | SYNTA PHARMACEUTICALS CORP. | 2017-11-09 | — | — | US | disclosed |
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2015-12-24 | — | — | US | disclosed |
| US-9206162-B2 | Triazole compounds that modulate Hsp90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-12-08 | — | — | US | disclosed |
| US-20150266858-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2015-09-24 | — | — | US | disclosed |
| US-9120745-B2 | Triazole compounds that modualte HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-09-01 | — | — | US | disclosed |
| US-9108933-B2 | Method for treating proliferative disorders associated with mutations in c-Met | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-18 | — | — | US | disclosed |
| US-9101614-B2 | Method for treating non-Hodgkin's lymphoma | SYNTA PHARMACEUTICALS CORP. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20150183771-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP (US) | 2015-07-02 | — | — | US | disclosed |
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-9006277-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORP. (US) | 2015-04-14 | — | — | US | disclosed |
| US-20130296378-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130072489-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8299107-B2 | Triazole compounds that modulate HSP90 activity | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-20120122869-A1 | TRIZAOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2012-05-17 | — | — | US | disclosed |
| US-20110319404-A1 | METHOD FOR TREATING NON-HODKIN'S LYMPHOMA | SYNTA PHARMACEUTICALS CORP. | 2011-12-29 | — | — | US | disclosed |
| US-8034834-B2 | Method for treating proliferative disorders with HSP90 inhibitors | SYNTA PHARMACEUTICALS CORP. (US) | 2011-10-11 | — | — | US | disclosed |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORP. | 2011-08-11 | — | — | US | disclosed |
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | SYNTA PHARMACEUTICALS CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110046125-A1 | METHOD FOR TREATING INFECTIONS | SYNTA PHARMACEUTICALS CORP. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | SYNTA PHARMACEUTICALS CORP. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105483-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90AA1, HSP90AB2P | HSP90AA1 2/4885HSP90AB1 1/4885MEN1 3743/4885 |
| US-20120122869-A1 | TRIZAOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, CDC37 | HSP90AA1 4/4885HSP90AB1 1/4885MEN1 4212/4885 |
| US-20110195094-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885MEN1 4367/4885 |
| US-20150174134-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | HSP90AA1 8/4885HSP90AB1 6/4885MEN1 4029/4885 |
| US-20130296378-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885MEN1 4367/4885 |
| US-20150183771-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885MEN1 4367/4885 |
| US-20110319404-A1 | METHOD FOR TREATING NON-HODKIN'S LYMPHOMA | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885MEN1 4111/4885 |
| US-20150366885-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885MEN1 4367/4885 |
| US-20100249185-A1 | METHOD FOR INHIBITING TOPOISOMERASE II | TOP2A, TOP2B, TOP1 | HSP90AA1 8/4885HSP90AB1 6/4885MEN1 4029/4885 |
| US-20170320837-A1 | METHOD FOR TREATING INFLAMMATORY DISORDERS | TNF, IL2, IL5 | HSP90AA1 531/4885HSP90AB1 605/4885MEN1 4212/4885 |
| US-20110046125-A1 | METHOD FOR TREATING INFECTIONS | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885MEN1 4528/4885 |
| US-20150266858-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885MEN1 4367/4885 |
| US-20130072489-A1 | TRIAZOLE COMPOUNDS THAT MODULATE HSP90 ACTIVITY | HSP90AB1, HSP90B1, HSP90AA1 | HSP90AA1 3/4885HSP90AB1 1/4885MEN1 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.